NICE gives the go ahead for the use of Xolair® (omalizumab) to treat potentially disabling skin condition

Novartis is delighted that the National Institute of Health and Care Excellence (NICE) has recommended Xolair® (omalizumab) as an option for add-on therapy for treating severe CSU for adults...